EA202091865A1 - Композиции и способы для снижения экспрессии tau - Google Patents
Композиции и способы для снижения экспрессии tauInfo
- Publication number
- EA202091865A1 EA202091865A1 EA202091865A EA202091865A EA202091865A1 EA 202091865 A1 EA202091865 A1 EA 202091865A1 EA 202091865 A EA202091865 A EA 202091865A EA 202091865 A EA202091865 A EA 202091865A EA 202091865 A1 EA202091865 A1 EA 202091865A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- methods
- tau
- expression
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение относится к композициям и к способам для снижения уровня экспрессии мРНК и белка tau. Эти композиции и способы могут быть применены для лечения tau-ассоциированных заболеваний и расстройств.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562270165P | 2015-12-21 | 2015-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091865A1 true EA202091865A1 (ru) | 2021-01-29 |
Family
ID=57758674
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891468A EA036417B1 (ru) | 2015-12-21 | 2016-12-19 | Композиции и способы для снижения экспрессии tau |
EA202091865A EA202091865A1 (ru) | 2015-12-21 | 2016-12-19 | Композиции и способы для снижения экспрессии tau |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891468A EA036417B1 (ru) | 2015-12-21 | 2016-12-19 | Композиции и способы для снижения экспрессии tau |
Country Status (30)
Country | Link |
---|---|
US (2) | US11473083B2 (ru) |
EP (1) | EP3394259B1 (ru) |
JP (3) | JP7027328B2 (ru) |
KR (1) | KR20180089517A (ru) |
CN (2) | CN116218848A (ru) |
AR (1) | AR107579A1 (ru) |
AU (2) | AU2016376034B2 (ru) |
BR (1) | BR112018012304A2 (ru) |
CA (1) | CA3008094A1 (ru) |
CL (3) | CL2018001652A1 (ru) |
CO (1) | CO2018006297A2 (ru) |
CR (1) | CR20200609A (ru) |
CU (1) | CU24574B1 (ru) |
DO (1) | DOP2018000151A (ru) |
EA (2) | EA036417B1 (ru) |
EC (1) | ECSP18050575A (ru) |
HK (1) | HK1254822A1 (ru) |
IL (3) | IL296844B2 (ru) |
JO (2) | JOP20200228A1 (ru) |
MX (2) | MX2018007726A (ru) |
MY (1) | MY191737A (ru) |
PE (1) | PE20181448A1 (ru) |
PH (1) | PH12018501207A1 (ru) |
RU (1) | RU2747734C2 (ru) |
SA (1) | SA518391831B1 (ru) |
SG (2) | SG10201913434PA (ru) |
SV (1) | SV2018005714A (ru) |
TW (1) | TWI787163B (ru) |
UY (1) | UY37038A (ru) |
WO (1) | WO2017109679A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2866392C (en) | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ma公司 | 用於調節τ蛋白表現之組合物 |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
MX2020009532A (es) * | 2018-03-13 | 2020-10-05 | Janssen Pharmaceutica Nv | Oligonucleotidos modificados para uso en el tratamiento de tauopatias. |
CA3103054A1 (en) | 2018-07-03 | 2020-01-09 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating tau expression |
JP2023521604A (ja) * | 2020-03-30 | 2023-05-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
CN113817728A (zh) * | 2020-06-19 | 2021-12-21 | 四川大学华西医院 | 一种有效干扰Tau蛋白表达的重组慢病毒及其应用 |
EP4355878A1 (en) * | 2021-06-16 | 2024-04-24 | Empirico Inc. | Treatment of mtres1 related diseases and disorders |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
ATE271064T1 (de) | 1990-01-11 | 2004-07-15 | Isis Pharmaceuticals Inc | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US20020052331A1 (en) | 1990-08-14 | 2002-05-02 | Brenda Baker | Compositions and methods for antisense inhibition of protein translation |
US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
DK0618968T3 (da) | 1991-12-06 | 2000-04-10 | Max Planck Gesellschaft | Midler til diagnostisering og behandling af Alzheimer's sygdom |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
CA2116460A1 (en) | 1993-03-02 | 1994-09-03 | Mitsubishi Chemical Corporation | Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being |
KR940021073A (ko) | 1993-03-02 | 1994-10-17 | 미야베 요시가즈 | 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i |
NZ266386A (en) | 1993-05-11 | 1997-11-24 | Univ North Carolina | Use of antisense rna oligonucleotides in regulating gene expression |
CA2246229C (en) | 1996-02-14 | 2011-08-23 | Isis Pharmaceuticals Inc. | Sugar-modified gapped oligonucleotides |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
JP2002513551A (ja) | 1998-05-01 | 2002-05-14 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 病原性タウ突然変異 |
US6664443B1 (en) | 1998-05-01 | 2003-12-16 | Mayo Foundation For Medical Education And Research | Pathogenic Tau mutations in transgenic mice |
TW200532020A (en) * | 1998-07-14 | 2005-10-01 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6350868B1 (en) | 1999-04-26 | 2002-02-26 | University Of North Carolina At Chapel Hill | Antisense human fucosyltransferase sequences and methods of use thereof |
CN101284873A (zh) * | 1999-06-30 | 2008-10-15 | 科里克萨有限公司 | 用于肺癌治疗和诊断的组合物和方法 |
AU2001229619A1 (en) | 2000-01-21 | 2001-07-31 | Pharmacia And Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
AU2001241839A1 (en) * | 2000-02-28 | 2001-09-12 | Decode Genetics Ehf | Human schizophrenia gene |
AU2002231741A1 (en) | 2001-01-11 | 2002-07-24 | Bayer Aktiengesellschaft | Regulation of human tau-tubulin kinase |
WO2004003134A2 (en) | 2002-06-26 | 2004-01-08 | Isis Pharmaceuticals, Inc. | Antisense inhibition via rnase h-independent reduction in mrna |
US20050130924A1 (en) | 2002-06-26 | 2005-06-16 | Monia Brett P. | Antisense inhibition via RNAse H-independent reduction in mRNA |
US20080176812A1 (en) | 2002-08-05 | 2008-07-24 | Davidson Beverly L | Allele-specific silencing of disease genes |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
ES2352668T3 (es) | 2002-08-14 | 2011-02-22 | Mitsubishi Chemical Medience Corporation | Anticuerpo específico para una proteína tau del sistema nervioso central. |
US7906326B2 (en) | 2003-05-07 | 2011-03-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof |
US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US20070077553A1 (en) | 2003-10-30 | 2007-04-05 | Rosetta Genomics | Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof |
US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US20130130231A1 (en) | 2002-11-26 | 2013-05-23 | Isaac Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US7696334B1 (en) | 2002-12-05 | 2010-04-13 | Rosetta Genomics, Ltd. | Bioinformatically detectable human herpesvirus 5 regulatory gene |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
AU2003904328A0 (en) | 2003-08-13 | 2003-08-28 | Garvan Institute Of Medical Research | Diagnosis and treatment of neurodegenerative disorders |
WO2005021749A1 (en) | 2003-08-28 | 2005-03-10 | Novartis Ag | Interfering rna duplex having blunt-ends and 3’-modifications |
WO2005040382A2 (de) | 2003-10-28 | 2005-05-06 | Alexander Cherkasky | Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende |
US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
EP1784501B1 (en) * | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
DK1766010T3 (da) | 2004-06-28 | 2011-06-06 | Univ Western Australia | Antisense-oligonukleotider til induktion af exon-skipping og fremgangsmåder til anvendelse deraf |
US7312035B2 (en) | 2004-09-03 | 2007-12-25 | Affymetrix, Inc. | Methods of genetic analysis of yeast |
US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
CN101102789B (zh) | 2004-12-03 | 2012-05-30 | 罗得岛医院 | 阿尔茨海默病的诊断和治疗 |
US20070048756A1 (en) | 2005-04-18 | 2007-03-01 | Affymetrix, Inc. | Methods for whole genome association studies |
WO2007028065A2 (en) | 2005-08-30 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
US8258109B2 (en) | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
GB0605337D0 (en) * | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20090280110A1 (en) | 2006-06-27 | 2009-11-12 | University Of Virginia Patent Foundation | Cell Model for Alzheimer's Disease Pathology |
CA2681568C (en) | 2006-11-23 | 2019-01-08 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
JP5721426B2 (ja) | 2007-04-05 | 2015-05-20 | ザ ジェイ.ディヴィッド グラッドストン インスティテューツ | 神経の過度な興奮を緩和する薬剤を識別する方法 |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US9034837B2 (en) | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
NZ626359A (en) | 2009-11-12 | 2016-02-26 | Univ Western Australia | Antisense molecules and methods for treating pathologies |
WO2011094645A1 (en) | 2010-01-28 | 2011-08-04 | University Of Massachusetts Lowell | Methods of diagnosing tau-associated neurodegenerative diseases |
US20130079505A1 (en) | 2010-03-24 | 2013-03-28 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
JP6336755B2 (ja) | 2010-11-12 | 2018-06-06 | ザ ジェネラル ホスピタル コーポレイション | ポリコームに関連する非コードrna |
US9145557B2 (en) | 2010-11-23 | 2015-09-29 | Mirrx Therapeutics A/S | Oligonucleotides for modulation of target RNA activity |
CA2822462A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
EP3495497B1 (en) * | 2011-04-28 | 2021-03-24 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
CA2866392C (en) | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
JP6243919B2 (ja) | 2012-10-24 | 2017-12-06 | フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー. ファオ.Fraunhofer−Gesellschaft Zur Forderung Der Angewandten Forschung E. V. | 微小管修飾化合物 |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
EP3885439A1 (en) | 2012-12-20 | 2021-09-29 | Sarepta Therapeutics, Inc. | Improved exon skipping compositions for treating muscular dystrophy |
JP6629716B2 (ja) | 2013-03-14 | 2020-01-15 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | タウ発現を調節するための組成物および方法 |
HUE042218T2 (hu) | 2013-03-14 | 2019-06-28 | Sarepta Therapeutics Inc | Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére |
CN105378081B (zh) | 2013-03-14 | 2019-06-14 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
US20160367587A1 (en) | 2013-06-12 | 2016-12-22 | Oncoimmunin, Inc. | Systemic In Vivo Delivery of Oligonucleotides |
TW202246503A (zh) * | 2013-07-19 | 2022-12-01 | 美商百健Ma公司 | 用於調節τ蛋白表現之組合物 |
WO2015068075A2 (en) | 2013-10-24 | 2015-05-14 | Institut National De La Sante Et De La Recherche Medicale | Detection of tau |
WO2016011123A1 (en) * | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
US20170211064A1 (en) | 2014-07-29 | 2017-07-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
US11761951B2 (en) | 2015-02-04 | 2023-09-19 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
MX2017010066A (es) * | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
US20170035860A1 (en) * | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
-
2015
- 2015-12-21 JO JOP/2020/0228A patent/JOP20200228A1/ar unknown
-
2016
- 2016-12-19 US US15/383,452 patent/US11473083B2/en active Active
- 2016-12-19 EA EA201891468A patent/EA036417B1/ru not_active IP Right Cessation
- 2016-12-19 JO JOP/2016/0266A patent/JO3790B1/ar active
- 2016-12-19 SG SG10201913434PA patent/SG10201913434PA/en unknown
- 2016-12-19 CA CA3008094A patent/CA3008094A1/en active Pending
- 2016-12-19 MY MYPI2018702190A patent/MY191737A/en unknown
- 2016-12-19 IL IL296844A patent/IL296844B2/en unknown
- 2016-12-19 AR ARP160103917A patent/AR107579A1/es unknown
- 2016-12-19 SG SG11201804704PA patent/SG11201804704PA/en unknown
- 2016-12-19 WO PCT/IB2016/057794 patent/WO2017109679A1/en active Application Filing
- 2016-12-19 MX MX2018007726A patent/MX2018007726A/es unknown
- 2016-12-19 CN CN202211714988.9A patent/CN116218848A/zh active Pending
- 2016-12-19 EA EA202091865A patent/EA202091865A1/ru unknown
- 2016-12-19 IL IL305866A patent/IL305866A/en unknown
- 2016-12-19 BR BR112018012304A patent/BR112018012304A2/pt active Search and Examination
- 2016-12-19 UY UY0001037038A patent/UY37038A/es active IP Right Grant
- 2016-12-19 KR KR1020187020632A patent/KR20180089517A/ko unknown
- 2016-12-19 RU RU2018126545A patent/RU2747734C2/ru active
- 2016-12-19 JP JP2018550880A patent/JP7027328B2/ja active Active
- 2016-12-19 PE PE2018001176A patent/PE20181448A1/es unknown
- 2016-12-19 AU AU2016376034A patent/AU2016376034B2/en active Active
- 2016-12-19 TW TW105142107A patent/TWI787163B/zh active
- 2016-12-19 EP EP16823350.0A patent/EP3394259B1/en active Active
- 2016-12-19 CR CR20200609A patent/CR20200609A/es unknown
- 2016-12-19 CN CN201680082326.0A patent/CN109072237B/zh active Active
- 2016-12-19 CU CU2018000065A patent/CU24574B1/es unknown
-
2018
- 2018-06-07 PH PH12018501207A patent/PH12018501207A1/en unknown
- 2018-06-18 SV SV2018005714A patent/SV2018005714A/es unknown
- 2018-06-18 CO CONC2018/0006297A patent/CO2018006297A2/es unknown
- 2018-06-18 IL IL260124A patent/IL260124A/en unknown
- 2018-06-18 CL CL2018001652A patent/CL2018001652A1/es unknown
- 2018-06-19 SA SA518391831A patent/SA518391831B1/ar unknown
- 2018-06-20 DO DO2018000151A patent/DOP2018000151A/es unknown
- 2018-06-21 MX MX2023008211A patent/MX2023008211A/es unknown
- 2018-07-05 EC ECSENADI201850575A patent/ECSP18050575A/es unknown
- 2018-10-31 HK HK18113913.7A patent/HK1254822A1/zh unknown
-
2019
- 2019-01-18 CL CL2019000149A patent/CL2019000149A1/es unknown
- 2019-11-25 CL CL2019003420A patent/CL2019003420A1/es unknown
-
2020
- 2020-11-13 AU AU2020267282A patent/AU2020267282B2/en active Active
-
2021
- 2021-04-28 JP JP2021076622A patent/JP2021118732A/ja active Pending
-
2022
- 2022-02-15 JP JP2022021494A patent/JP2022065096A/ja active Pending
- 2022-07-20 US US17/813,843 patent/US20220411796A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091865A1 (ru) | Композиции и способы для снижения экспрессии tau | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
EA201991183A1 (ru) | Новые ингибиторы глутаминазы | |
BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201890810A1 (ru) | Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
EA201890364A1 (ru) | СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t | |
EA201790484A1 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
EA201791937A1 (ru) | Противовоспалительные полипептиды | |
EA201592012A1 (ru) | Применение флагеллина для улучшенной химиотерапии |